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Abstract 
Background and Purpose 
The synthetic vitamin D3 analog paricalcitol acts as a selective activator of vitamin D 
receptor (VDR). While there is evidence for cardioprotective effects of paricalcitol associated 
with the VDR pathway, less information is available about the structural and functional 
cardiac effects of paricalcitol on established heart failure (HF), and particularly its effects on 
associated electrophysiological or Ca2+-handling remodelling. 
Experimental Approach 
We used a murine model of transverse aortic constriction (TAC) to study the effect of 
paricalcitol on established HF. Treatment was initiated 4 weeks after surgery over 5 
consecutive weeks and mice were sacrificed 9 weeks after surgery. Cardiac magnetic 
resonance imaging (CMRI) was performed 4 and 9 weeks after surgery. Hearts were used for 
biochemical and histological studies and to isolate ventricular myocytes for 
electrophysiological and calcium imaging studies. 
Key Results 
CMRI analysis revealed that, compared with vehicle, paricalcitol treatment prevented the 
progression of ventricular dilation and hypertrophy after TAC and halted the corresponding 
decline in ejection fraction. These beneficial effects were related to the attenuation of 
intracellular Ca2+-mishandling remodelling, antifibrotic and antihypertrophic effects, and 
potentially antiarrhythmic effects by preventing the reduction of K+ current density and the 
long QT, JT and TpTe intervals observed in HF animals.  
Conclusions and implications 
The results suggest that paricalcitol treatment in established HF hampers disease progression 
and improves adverse electrophysiological and Ca2+ handling remodelling, attenuating the 
vulnerability to HF-associated ventricular arrhythmias. Paricalcitol may emerge as a potential 
therapeutic option in the treatment of HF. 
Key words: Paricalcitol, K+ currents, transverse aortic constriction, heart failure, 
electrophysiological remodelling, Ca2+ handling remodelling, cardiac fibrosis, QT interval, 
JT interval, TpTe interval.  
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Abbreviations 
Parathyroid hormone (PTH), heart failure (HF), left ventricle (LV), ejection fraction (EF), 
cardiac magnetic resonance imaging (CMRI), vitamin D receptor (VDR), transverse aortic 
constriction (TAC), left ventricular mass (LVM), left ventricular hypertrophy (LVH), left 
ventricle end-diastolic volume (LVEDV), left ventricle end-systolic volume (LVESV), left 
ventricular ejection fraction (LVEF) heart weight (HW), tibia length (TL), sarcoplasmic 
reticulum (SR), heart rate (HR). Ventricular electrocardiographic repolarization parameters: 
interval between QRS end J point and the end of the T wave (JT interval), the interval from 
the peak to the end of the T wave (TpTe), the fast transient outward current (Itof), the 
ultrarapid delayed rectifier K+ current (Ikur) and the non-inactivating steady-state outward 
current (Iss). 
 
BULLET POINT SUMMARY 
What is already known: 
 Depressed cardiac function in HF is commonly associated with impairment of Cai2+ 
handling.  
 HF is associated with an increased incidence of malignant arrhythmias and sudden 
death.  
What this study adds:  
 Paricalcitol treatment on established HF prevents Ca2+ mishandling  
 Paricalcitol treatment counteracts the down-regulation of K+ currents associated with 
HF. 
Clinical significance:  
 Paricalcitol treatment reduces LVH, fibrosis and adverse electrophysiological and 
Ca2+ handling remodelling. 
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INTRODUCTION 
Chronic heart failure (HF) is a major public health concern in ageing societies and a leading 
cause of hospitalisation and mortality (Ponikowski et al., 2014, Savarese and Lund, 2017). 
The disorder is usually accompanied by progression from adaptive to maladaptive 
hypertrophy and also cardiac dilation and dimished left ventricular ejection fraction (LVEF). 
Adverse cardiac remodelling is an important determinant of the clinical outcome of HF and is 
linked to disease progression and poor prognosis (Heusch et al., 2014). Ventricular 
remodelling encompasses cardiomyocyte hypertrophy, pro-fibrotic responses and 
downregulation of K+ currents, which alter the electrotonic coupling between cells and 
prolongs QT intervals, overall increasing the risk of ventricular arrhythmias and sudden 
cardiac death (Nass et al., 2008, Tomaselli et al., 1994). Depressed cardiac function in HF is 
also commonly associated with impairment of intracellular Ca2+ handling. In this regard, 
failing hearts often show depressed systolic Ca2+ release and lower sarcoplasmic reticulum 
(SR)-Ca2+ load, which compromises cell contractility (Val-Blasco et al., 2017, Gómez-
Hurtado et al., 2017, Ruiz-Hurtado et al., 2015). 
Over the past 25 years, considerable progress has been made in the treatment of chronic HF 
using angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers, 
and also mineralocorticoid receptor antagonists, β-receptor blockers and resynchronisation 
therapy (Owens et al., 2016). The pharmacological treatment of HF aims to halt progressive 
cardiac hypertrophy and LVEF decline; however, as many as 25–40% of all patients die from 
chronic HF within 1 year of diagnosis. New therapies are entering clinical trials yearly 
(Nabeebaccus et al., 2016, Tamargo et al., 2018), but the identification of new targets with 
therapeutic potential in HF continues to be an area of great interest. 
Paricalcitol (19-nor-1alpha, 25-dihydroxyvitamin D2) is a synthetic vitamin D3 analog that 
acts as a selective activator of the vitamin D receptor (VDR), and is indicated for the 
prevention and treatment of secondary hyperparathyroidism associated with chronic kidney 
disease (Robinson and Scott, 2005). There is a growing body of work demonstrating 
beneficial cardioprotective properties associated with the VDR pathway (Gardner et al., 2013, 
Meredith and McManus, 2013, Norman and Powell, 2014). Yet, little information is available 
on the cardiac structural and functional effects of paricalcitol on established HF. Likewise, 
there is a paucity of evidence on the effect of paricalcitol on arrhythmogenic disorders, or 
Ca2+ handling remodelling associated with established HF.  
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In the present study, we used a murine model of HF induced by pressure overload (transverse 
aortic constriction, TAC) to test the hypothesis that paricalcitol treatment blocks the 




Male C57BL/6J mice (24-29 g, 10 weeks of age) were used in all experiments.  Mice were 
bred and housed under specific pathogen-free conditions in the Experimental Animal Centre 
of the Biomedical Research Institute “Alberto Sols” CSIC-UAM/CIBER-CV, Madrid, Spain. 
All experiments were performed after approval of the Bioethical Committee of the Consejo 
Superior de Investigaciones Cientificas (Proex 035-15), following the guidelines for ethical 
care of experimental animals of the European Union (2012/63/EU) and in accordance with 
the ARRIVE guidelines for reporting experiments involving animals (Kilkenny et al., 2010, 
McGrath et al., 2010). Animals were maintained at controlled temperature (23–25°C) on a 
12-hour light/dark cycle with ad libitum access to water and a standard diet (Teklad Global 
14% Protein Rodent maintenance Diet, Harlan Laboratories Inc., Indianapolis, IN) that 
contained 600 IU g-1 of vitamin D3 (cholecalciferol). The animal cages (Polysulfone type SII, 
Techniplast, Italy) were 553 cm2 by 20.8 cm depth and animals were housed with a 
maximum of 4 mice per cage. 
  
Transverse aortic constriction  
Animals were anaesthetised by i.p. injection of a mixture of ketamine (100 mg kg-1) and 
xylazine (10 mg kg-1). Adequacy of anesthesia was determined by assessing loss of 
withdrawal reflex. Mice were then intubated and underwent trans-sternal thoracotomy. The 
transverse aorta was constricted with a 6-0 black braided silk suture tied against a 27-gauge 
needle, as described by Rockman (Rockman et al., 1991). A similar procedure was followed 
for sham-operated mice, but no suture was tied. Mice were given subcutaneous 
buprenorphine (1 mg kg-1) for pain relief before and after the surgery. A heated pad was used 
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Study design 
A scheme of the experimental approach is shown in Figure 1. Animals were distributed into 
two experimental groups: SHAM-operated and TAC-operated. Cardiac structure and function 
were analysed by cardiac magnetic resonance imaging (CMRI) 4 weeks after surgery. At this 
point, only TAC operated mice with EF <58% and with significant LV dilation were included 
in the TAC group. The mice were then blind randomised to the vehicle or paricalcitol 
treatment groups, with each group originally consisting of 16 mice. Treatment with vehicle 
(water for injection, 3.9% propylene glycol and 1.3% ethyl alcohol) or with, 300 ng kg-1 
paricalcitol (Normon S.A. Madrid, Spain) was delivered by i.p. injection 3 times weekly 
(Monday, Wednesday and Friday) for 5 consecutive weeks. CMRI was repeated after the 5 
weeks of treatment (9 weeks after the surgery). Also, a standard ECG was performed and 
blood samples were drawn from the retro-orbital plexus. Finally, mice were sacrificed and 
hearts were excised, weighed and prepared for biochemical and histological studies. In some 
experiments, hearts were retrogradely perfused through the aorta using a modified 
Langendorff apparatus to isolate ventricular myocytes (see below).  
CMRI data pre-surgery were not performed because the aim of the study was to analyze the 
effect of paricalcitol on established HF. Therefore, control values were those obtained in the 
SHAM group 4 and 9 weeks after the surgery. 
Macroscopic parameters, cell capacitance and serum analysis  
The heart weight (HW) to tibia length (TL) ratio was measured as an index of cardiac 
hypertrophy (Table 1). Cardiomyocyte surface area was quantified using LSM Zeiss Image 
Browser 4.2 software (Carl Zeiss, Germany) (Table 1) and the membrane capacitance of the 
cardiomyocytes was evaluated using the whole-cell configuration of the patch-clamp 
technique (see below) (Table 1). Blood samples were centrifuged at 2500 rpm for 5 min to 
obtain blood serum. A parathyroid hormone (PTH) assay was performed using the Mouse 
PTH 1-84 ELISA Kit (Immutopics, San Clemente, CA). Calcium and phosphorus assays 
were performed using colorimetric assays kits (Calcium Assay Kit and Phosphate Assay Kit, 
respectively; Abcam, Cambridge, UK) on an EnSpireTM Multimode Plate Reader (Perkin 
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Cardiac magnetic resonance imaging  
CMRI was carried out on a 7.0 Tesla MR system (Bruker Pharmascan, Bruker, Ettlingen, 
Germany). Analysis was performed in the Biomedical Research Institute “Alberto Sols” 
CSIC-UAM. Mice were anesthetised with an isoflurane and oxygen mixture (2% in 1L min-1 
for induction and 1.5% during the acquisition). The temperature of the animals was 
monitored and maintained at 35–36ºC during the experiments. Heart and respiratory rates 
were recorded using the 1025 SAM monitoring and gating system (SA Instruments, Inc., 
New York, NY). Several images were acquired to localise the short axis planes. After 
position adjustment, 6 to 12 slices were acquired to cover the entire heart. Each slice 
consisted of 20 gated frames synchronised with the cardiac cycle. For image acquisition, we 
used the Intragate FLASH sequence with the following parameters: echo time (TE) = 1.262 
ms; field of view (FOV) = 3 × 3 cm2; slice thickness = 0.8 mm; matrix size = 256 × 256. The 
acquired data were zero-filled to achieve a reconstructed matrix size of 256 × 256. Images 
were analysed using SEGMENT v2.0 R5642 (http://segment.heiberg.se). Six slices were 
selected from each heart and analysed by manual segmentation of left ventricular endocardial 
and epicardial borders in all the image frames. After segmentation of the images, SEGMENT 
was used to automatically calculate the following functional parameters: left ventricle end-
diastolic volume (LVEDV) (μL) and left ventricle end-systolic volume (LVESV) (μL), 
ejection fraction (EF) (%) and left ventricle mass (LVM) (mg). LVM was estimated by LV 
wall volume × the specific gravity of the myocardium (1.05 g/cm3). 
ECG recordings 
ECG recordings were obtained on the Small Animal Physiological Monitoring System 
(Harvard Apparatus, Holliston, MA). Mice were located in prone position on a warm pad at 
37ºC during the recordings and were lightly anesthetised with an isoflurane and oxygen 
mixture (1.5%). ECG recordings were obtained under basal conditions for 5 minutes. ECG 
registries were converted into LabChart binary files using a cross-platform Java program. 
Files were analysed in a blinded fashion using LabChart 7.0 software (AD Instruments, 
Sydney, Australia) (RRID:SCR_017551). 
Histology 
Sirius red staining was performed on paraffin sections to measure fibrosis. Tissue samples 
were dehydrated, embedded in paraffin and cut into sections (5-μm thickness). Slices were 
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stained with sirius red (Direct Red 80) (25 mL of 10% aqueous Direct Red in 225 mL of 
1.3% aqueous picric acid; Sigma-Aldrich Chemical Company, Madrid, Spain). Quantification 
of collagen content was performed using ImageJ software (NIH) (RRID:SCR_003070) and 
expressed as the perivascular fibrosis area divided by vessel lumen area, and as a percentage 
of interstitial fibrosis over the total amount of tissue, excluding lumen and perivascular 
fibrosis. A single investigator blinded to the experimental groups performed the analysis. 
Total RNA isolation and real-time PCR  
Total RNA was extracted from a portion of the left ventricle of representative mice of each 
experimental group using the RNeasy Mini Kit on a QIAcube robotic workstation (both from 
Qiagen, Hilden, Germany) and was quantified using a NanoDrop spectrophotometer 
(NanoDrop Technologies, Wilmington, DE). In total, 250 ng of RNA was retrotranscribed 
using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, 
CA) and real-time PCR was performed on an ABI 7900HT Fast Real-Time PCR platform 
(Applied Biosystems). The endogenous Rplp0 gene (36B4) was used as reference for fold-
induction calculations using the ∆∆Ct method. 
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Cardiomyocyte isolation 
 
Adult single ventricular cardiomyocytes were isolated as reported previously (Delgado et al., 
2015). Briefly, mice were heparinised and anesthetised with ketamine (100 mg kg-1) and 
xylazine (10 mg kg-1) by i.p. injection. Adequacy of anesthesia was determined by assessing 
loss of withdrawal reflex. Hearts were then rapidly removed and retrogradely perfused 
through the aorta using a modified Langendorff apparatus. Hearts were perfused for 2–3 min 
at 36–37ºC with a standard calcium-free Tyrode’s solution containing 0.2 mM EGTA, and 
then for 3–4 min with the same Tyrode’s solution containing collagenase type II (251 IU mL-
1, Worthington Biochemical, Lakewood, NJ) and 0.1 mM CaCl2. After perfusion, the hearts 
were removed from the Langendorff apparatus and the ventricles were chopped into small 
pieces and gently stirred for 2–5 min in a standard Tyrode’s solution containing 0.1 mmol L-1 
CaCl2, collagenase (251 IU mL
-1) and BSA (Sigma-Aldrich) to disperse the isolated 
ventricular myocytes. Cell suspensions were filtered through a 250 µm nylon mesh, pelleted 
by centrifugation for 3 min at 20 × g and suspended in Tyrode’s solution containing 0.5 
mmol L-1 CaCl2 and BSA. Cells were centrifuged as before and suspended in a storage 
solution containing 1 mmol L-1 CaCl2 and BSA. Standard calcium-free Tyrode’s solution 
contained in mmol L-1: 130 NaCl, 5.4 KCl, 0.4 NaH2PO4, 0.5 MgCl2, 25 HEPES, 22 glucose; 
the pH was adjusted to 7.4 with NaOH. Single rod-shaped and Ca2+-tolerant cells with clear 
cross-striations were used for electrophysiological and intracellular Ca2+ imaging studies.  
 
Electrophysiological studies 
Isolated ventricular myocytes were placed in a chamber mounted on the stage of an inverted 
microscope and allowed to adhere for 5 min before being superfused with external solution. 
Whole-cell voltage-clamp recordings were obtained in the ruptured patch configuration using 
an Axopatch 200B patch clamp amplifier (Molecular Devices, Sunnyvale, CA). The patch 
pipette resistance for K+ current recordings was 1–2 MΩ and was filled with a solution 
containing in mmol L-1: 135 KCl, 4 MgCl2, 5 EGTA, 10 HEPES, 10 glucose, 5 Na2ATP, and 
3 disodium creatine phosphate; the pH was adjusted to 7.2 with KOH. Whole-cell voltage 
clamp experiments were performed at room temperature (24–26ºC). 
In the adult mouse ventricle, the repolarising K+ currents involve three components that can 
be identified by their specific voltage dependence and their sensitivity to pharmacological 
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agents. First, total K+ currents (IK
+) were elicited by applying 300 ms depolarising steps from 
-50 mV to +50 mV (with 10 mV steps) from a holding potential of -80 mV at a frequency of 
0.2 Hz. Then, the fast transient outward current (Itof), the ultrarapid delayed rectifier K
+ 
current (Ikur) and the non-inactivating steady-state outward current (Iss) were obtained as 
previously reported (Tamayo et al., 2018). The external solution for IK+ recordings contained 
in mmol L-1: 135 NaCl, 10 glucose, 10 HEPES, 1 MgCl2, 1 CaCl2, 4 KCl, and 2 CoCl2; the 
pH was adjusted to 7.4 with NaOH.  
L-type Ca2+ currents (ICaL) were elicited by applying 300 ms depolarising voltage  pulses 
from a holding potential of -50 mV, between -40 to +60 mV (with 10 mV steps) at a 
frequency of 0.2 Hz. Ca2+ currents were normalised to cell capacitance to obtain current 
density. The external Tyrode’s solution for ICaL recordings contained in mmol L
-1: 140 NaCl, 
1.1 MgCl2, 5.4 CsCl, 10 glucose, 5 HEPES, 1.8 CaCl2; the pH was adjusted to 7.4 with 
CsOH. The intracellular recording pipette solution for whole-cell experiments contained in 
mmol L-1: 100 CsCl, 20 TEACl, 5 EGTA, 10 HEPES, 5 Na2ATP, 0.4 Na2GTP, 5 Na2 creatine 
phosphate, 0.06 CaCl2; the pH was adjusted to 7.2 with CsOH. 
Current density was calculated from peak K+ currents or current amplitude (ICaL) normalised 
to the membrane capacitance. Membrane capacitance (Cm) (Table 1) was elicited by applying 
± 10 mV voltage steps from -60 mV and Cm was calculated according to the following 
equation: 
Cm=τc I0/ Vm [1-(I∞/I0)] 
where τc is the time constant of the membrane capacitance, I0 the maximum capacitance 
current value,  Vm the amplitude of the voltage step, and I∞  the amplitude of the steady-state 
current. 
Intracellular Ca2+ dynamics 
Changes in intracellular Ca2+ concentration ([Ca2+]i) were recorded in intact isolated 
cardiomyocytes. Cardiomyocytes were loaded with the fluorescent Ca2+ dye Fluo-3 
acetomethyl ester (Fluo-3 AM, Invitrogen) (5 µmol L-1). All recordings were carried out at 
room temperature (20–23°C). Images were recorded on a Meta Zeiss LSM 710 confocal 
microscope (40× oil inversion objective with a 1.2 NA), by scanning cells with an Argon 
laser every 1.54 s. Fluo-3 AM was excited at 488 nm and the emitted fluorescence was 
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collected at >505 nm. [Ca2+]i transients were recording in Fluo-3AM-loaded cardiomyocytes 
electrically stimulated at 2 Hz. The amplitude of [Ca2+]i transients  (F/F0) was calculated by 
normalising the maximal fluorescence by the basal fluorescence. Subtraction of the 
background fluorescence was carried out beforehand in both cases. Therefore, we calculated 
F/F0 as: (F-background)/(F0-background). The decay time constant of Ca
2+ transients (Tau) 
was measured by fitting the decay trace. Ca2+ sparks were recorded in quiescent cells and 
identified using an automated detection system and by employing a criterion that 
discriminated the detection of false events, as previously reported (Gómez-Hurtado et al., 
2017). SR-Ca2+ load was determined by rapid caffeine (10 mmol L-1) administration to 
deplete the SR of Ca2+ stores, after field-stimulation to reach the steady state of Ca2+ load.  
SERCA2a activity (k SERCA2a) was indirectly determined by subtracting the decay rate 
constant of caffeine-evoked [Ca2+]i transients from the decay rate constant of systolic [Ca
2+]i 
transients (Bode et al., 2011, Delgado et al., 2015). 
Data analysis was performed with homemade routines using IDL 8 software (Research 
System Inc. Boulder, CO) and designed by AM Gómez (UMR-S 1180, INSERM). Images 
were corrected for background fluorescence. Cardiomyocyte surface area was quantified with 
LSM Zeiss Image Browser 4.2 software (Carl Zeiss) (Table 1). 
 
Data and statistical analysis 
The data and statistical analysis comply with the recommendations on experimental design 
and analysis in pharmacology (Curtis et al., 2018). Data are expressed as mean ±SEM or 
mean ±SD when individual values were included in the plot. Statistical analysis was 
performed using GraphPad Prism v.6.0 (GraphPad Software Inc., La Jolla, CA) 
(RRID:SCR_002798). One‐way ANOVA was used to compare significance among groups. If 
ANOVA produced a significant value of F (p < 0.05) and there was no significant variance 
inhomogeneity, Bonferroni’s post hoc multicomparison analysis was applied. Paired 
Student’s t-test was used for comparison of resonance magnetic imaging data obtained in the 
same mouse 4 weeks and 9 weeks after surgery. All p-values were two-tailed and p-values 
<0.05 were considered as statistically significant. Statistical analysis was undertaken only for 
studies where each group size was at least 5. N = number of mice and n = number of 
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independent cardiomyocytes. The data that support the findings of this study are available 
from the corresponding author upon reasonable request. 
Nomenclature of Targets and Ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a, 2015b). 
RESULTS 
Paricalcitol treatment prevents the progression of established cardiac hypertrophy and 
heart failure   
Cardiac structure and function were evaluated by CMRI in the same mouse 4 weeks and 9 
weeks after the surgery. Figure 2A-D shows individual values of LVM, LVEDV, LVESV 
and EF, 4 weeks after the surgery, just prior to vehicle or paricalcitol treatment. LVM, 
LVEDV and LVESV were significantly increased and EF decreased in both TAC groups 
compared with sham groups. Moreover, there were no differences between the TAC and 
TAC-paricalcitol groups in any parameter before starting the treatment. Figure 3A shows 
CMR images of representative hearts 9 weeks after surgery; specifically, 4-chamber long-axis 
(upper panel) and 2-chamber short-axis (lower panel) views from the 4 experimental groups 
(sham, sham-paricalcitol, TAC and TAC-paricalcitol). The results of this analysis are shown 
in Figure 3B–E. Evaluation of LVM is represented in Figure 3B, and showed that LVM was 
maintained in both sham groups from 4 to 9 weeks. As mentioned, LVM was significantly 
higher in the TAC groups than in the sham groups 4 weeks after surgery. Notably, whereas 
LVM continued to increase over the next 5 weeks in the TAC-vehicle group, it remained 
stable in the TAC-paricalcitol group. These data strongly suggest that paricalcitol has a 
significant effect on preventing increases in cardiac mass in the setting of established cardiac 
hypertrophy. Quantification of the CMRI parameters LVEDV and LVESV is shown in 
Figure 3C and 3D, respectively. Both parameters significantly increased 4 weeks after the 
TAC surgery when compared with the sham group, indicating a dilation of the left ventricle 
(LV) that was significantly greater 9 weeks after the surgery. Treatment with paricalcitol for 
5 weeks once the LV dilation was present, significantly prevented the progression of both 
parameters. Consistent with these changes, the EF was significantly lower in the TAC groups 
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than in equivalent sham groups at 4 weeks after surgery (Figure 3E). The EF further 
decreased in the TAC-vehicle group at 9 weeks after surgery, whereas treatment with 
paricalcitol during 5 weeks inhibited the decline in EF. Taken together, these data suggest 
that paricalcitol blocks the functional and structural deleterious remodelling in this model of 
established HF. In addition, the beneficial effects of paricalcitol occurred in the absence of an 
increase in the serum concentration of Ca2+ or phosphate, but with a significant decrease in 
PTH indicating that the drug effectively activates VDR (Table 1). 
Paricalcitol improves [Ca2+]i mishandling remodelling associated with established heart 
failure  
Given that cardiac dysfunction and Ca2+ mishandling are closely related, we next determined 
whether the beneficial effects of the paricalcitol treatment regime were associated with 
changes to intracellular Ca2+ dynamics. 
First, we analysed the ICaL in cardiomyocytes using the patch-clamp technique in the whole 
cell configuration. As shown in Figure 4A, the mean values of current-voltage (IV) density 
curves for ICaL were similar between the 4 groups. We examined systolic Ca
2+ release by the 
analysis of [Ca2+]i transients in isolated cardiomyocytes field stimulated at 2 Hz. Figure 4B 
shows representative line-scan confocal images of [Ca2+]i transients in cells from the 4 
groups. Results showed that the amplitude of [Ca2+]i transients was significantly lower in the 
TAC-vehicle group than in the sham groups, which was accompanied by a slower decay time 
constant (Tau) (Figure 4C and 4D). These changes were also associated with a decrease in 
cell contractility in the TAC-vehicle group (Figure 4E). By contrast, cardiomyocytes obtained 
from TAC-paricalcitol mice showed similar values of Tau and amplitude of [Ca2+]i transients 
to those of the sham groups. Paricalcitol treatment also prevented the TAC-induced decrease 
in cell shortening (Figure 4E). To determine whether the impairment in the systolic Ca2+ 
release was related to changes in SR-Ca2+ load, we used caffeine administration to estimate 
the SR-Ca2+ load in representative cardiomyocytes of the 4 groups. As shown in Figure 4F, 
the amplitude of caffeine-evoked [Ca2+]i transients was lower in the TAC groups than in the 
sham groups, and this was significantly prevented after 5 weeks of paricalcitol treatment. 
Decreased SR-Ca2+ load, together with slower time decay of [Ca2+]i transients, would indicate 
a fault in SR-Ca2+ reuptake. Given that SR-Ca2+ ATPase (SERCA2a) plays a key role in SR-
Ca2+ uptake, we next analysed SERCA2a activity (k SERCA2a). Results showed that k 
SERCA2a was significantly lower in the TAC group (4.3 ± 0.6 s-1; n=21) than in the sham 
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group (5.6 ± 1.3 s-1; n=16) or the sham paricalcitol group (5.8 ± 1.8 s-1; n=11) (p<0.05), 
clearly indicating an impairment of SERCA2a function in cardiomyocytes from TAC hearts. 
Treatment of TAC mice with paricalcitol prevented this impairment (5.4 ± 1.7 s-1; n=17). We 
next used RT-PCR to look for possible changes in the expression levels of Atp2a2 
(SERCA2a) and Pln (Phospholamban), which could account for the functional impairment in 
SR-Ca2+ load and re-uptake and the modulation by paricalcitol treatment. As shown in Figure 
4G and 4H, expression of Atp2a2 and Pln was significantly lower in the TAC group than in 
the sham group, and paricalcitol treatment prevented the decrease in expression of both 
genes. In addition, Atp2a2/Pln ratio was calculated and similar values between groups were 
obtained (Supporting information Figure S1). These results indicate that paricalcitol prevents 
Ca2+ mishandling in HF by maintaining both systolic Ca2+ release and physiological SR-Ca2+ 
load. Since depressed SR-Ca2+ load in HF is usually associated with an increase diastolic 
Ca2+ leak, we next analysed the frequency of Ca2+ sparks in all experimental groups. As 
expected, the analysis of the frequency of Ca2+ sparks normalised to SR Ca2+ load in 
quiescent cardiomyocytes showed a significant increase in the number of these events in the 
TAC group as compared with sham-operated group. By contrast, the frequency of Ca2+ 
sparks was significantly lower in TAC group treated with paricalcitol and was similar to that 
found in sham-Paricalcitol group (Supporting information, Figure S2). These data 
demonstrate that paricalcitol treatment significantly prevents the increase in diastolic Ca2+ 
leak observed in isolated cardiomyocytes from TAC hearts mice.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Paricalcitol prevents the transcriptional and structural development of fibrosis in 
established heart failure 
Chronic pressure overload is commonly associated with myocardial fibrosis (Shimizu and 
Minamino, 2016). Accordingly, we next examined for fibrosis in heart tissue of the 4 
experiment groups 9 weeks after surgery. Figure 5A and B show representative sirius red-
stained images of perivascular (Figure 5A) and interstitial (Figure 5B) collagen. Histological 
and quantitative analysis showed that both parameters were significantly greater 9 weeks 
after TAC surgery (Figure 5C and 5D, respectively). Comparison of hearts from the TAC-
vehicle and TAC-paricalcitol groups revealed that the development of perivascular (Figure 
5C) and interstitial (Figure 5D) fibrosis was significantly attenuated in the latter. 
Cardiac fibrosis is related to excessive synthesis and accumulation of the matrix protein 
collagen, and to the increased expression of plasminogen activator (PAI-1) (Takeshita et al., 
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2004). Analysis of the expression of the pro-fibrotic genes Serpine-1 (PAI-1), Col1a1 
(Collagen-1) and Col3a1 (Collagen-3) revealed that the expression of all was significantly 
higher in the TAC-vehicle group than in the sham groups (Figure 5E–G). Of note, 
cardiomyocytes from the TAC-paricalcitol group displayed mRNA values of the pro-fibrotic 
genes very similar to those of the sham groups. These results clearly indicate that paricalcitol 
treatment hinders, at the transcriptional and structural level, the development of cardiac 
fibrosis in an established model of HF. 
Antihypertrophic effects of paricalcitol are related to inhibition of the 
calcineurin/NFAT pathway 
Histological examination of hearts after 9 weeks of TAC corroborated the existence of LVH, 
with an increase in the size of the LV cavity (Figure 6A), and evident cardiomyocyte 
hypertrophy (Figure 6B). Paricalcitol treatment significantly attenuated TAC-induced LVH, 
both at the macroscopic and cellular levels. As shown in Figure 5C and Table 1, the HW/TL 
ratio was significantly greater in the TAC-vehicle group than in the sham groups, whereas 
this parameter was not affected in the TAC-paricalcitol group. In addition, quantitative 
analysis of cardiomyocyte surface area in the 4 groups showed that cells from the TAC-
vehicle group were significantly larger than those from the sham groups (Figure 6 D and 
Table 1) and the TAC-induced increase in size was blocked by paricalcitol. The results from 
membrane capacitance analysis mirrored these findings (Table 1). To validate these results, 
we analysed the mRNA expression of atrial natriuretic peptide (ANP) (Nppa), a classic 
hypertrophic marker gene, in all groups, finding a pattern similar to that for the fibrosis 
marker genes (Figure 6E).  
Finally, because the calcineurin/NFAT pathway is recognised as one of the most important 
signal transduction cascades underlying cardiac hypertrophy (Molkentin et al., 1998), we 
analysed the expression of the calcineurin/NFAT target gene Rcan.1.4 (Regulator of 
calcineurin). As shown in Figure 6F, Rcan.1.4 expression was significantly higher in the 
TAC-vehicle group than in the sham groups and, as anticipated, paricalcitol significantly 
atenuated its expression. This result suggests that the calcineurin/NFAT pathway is likely a 
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Long QT, JT and TpTe intervals and reduced repolarising IK+ densities in mice with 
established heart failure are prevented by chronic paricalcitol administration. 
LVH and HF are strongly associated with long QT intervals and repolarisation-related 
arrhythmogenic disorders. Accordingly, we measured ECG signals in mice 9 weeks after 
TAC surgery to study the effect of pressure overload on QT interval and the possible 
influence of paricalcitol on this parameter. Representative ECG recordings of QT interval 
measurements are shown in Figure 7A and mean QT intervals in the 4 groups are represented 
in Figure 7B. The results revealed that mean QT intervals were significantly longer in the 
TAC-vehicle group than in the sham groups. Notably, the mean QT intervals in the TAC-
paricalcitol group were significantly shorter than in the TAC group and were similar to those 
in the sham groups. All of these changes occurred in the absence of alterations to the heart 
rate (Figure 7C). In addition to the QT interval, we analysed other parameters associated with 
ventricular electrocardiographic repolarization, namely, the JT interval (the interval between 
QRS end, J point, and the end of the T wave) and the TpTe interval (the interval from the 
peak to the end of the T wave). Both ECG parameters were increased in the TAC group and 
treatment with paricalcitol prevented their prolongation (Figure 7 D and 7E). 
K+ currents (IK+) are important contributors to repolarisation in healthy myocardium and a 
reduction in the densities of IK+ have been associated with the acquired long QT syndrome 
seen in LVH and HF (Marionneau et al., 2008, Choy et al., 1997). Figure 8A shows 
representative recordings of total IK+ density in cardiomyocytes isolated from the 4 different 
groups of mice and Figure 8B shows mean IV curves for IK+ density. IK+ densities were 
significantly lower in the TAC-vehicle group than in the sham groups. By contrast, IK+ 
densities in the TAC-paricalcitol group were similar to those of the sham paricalcitol group. 
In the adult mouse ventricle, outward K+ currents involved in the repolarisation phase, are 
composed of three components. Figures 8C, 8D and 8E show mean IV curves for Itof, Ikur and 
Iss densities, respectively, obtained in myocytes isolated from the 4 experimental groups. 
Mean values of all three components were significantly decreased in the TAC group for the 
three components as compared with sham or the sham-paricalcitol groups. One-way ANOVA 
of Itof, Ikur and Iss densities followed by Bonferroni’s multiple comparisons test at +50 mV in 
the 4 experimental groups, showed that the treatment with paricalcitol significantly prevented 
the decrease of Itof but not Ikur or Iss (Figure 8F, 8G and 8H, respectively). 
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These results indicate that paricalcitol prevents QT, JT and TpTe interval prolongation 




Paricalcitol is a synthetic vitamin D3 analog that functions as a selective activator of VDR, 
and has been shown to reduce PTH levels with very low hypercalcemic and 
hyperphosphatemic secondary effects (Martin et al., 1998, Hervás Sánchez et al., 2011). The 
recommended dosage of paricalcitol in humans ranges from 0.04 to 0.24 μg/kg administered 
as a bolus on alternate days (Robinson and Scott, 2005). In the present study, we used 0.3 
μg/kg paricalcitol by i.p. injection 3 times weekly (Monday, Wednesday and Friday) for 5 
consecutive weeks. A large body of work demonstrates that the selective activation of VDR 
modulates, directly or indirectly, the transcriptional activity of hundreds of genes and 
modifies several enzymes and signalling pathways. Many of these pathways are involved in 
regulatory processes related to the parathyroid gland, gut and bone, but others are involved in 
non-classical actions of VDR, including those of potential relevance to cardiovascular 
diseases such as contractile function, hypertrophy, fibrosis, neurohormonal activation and 
inflammation (Lavie et al., 2011, Meredith and McManus, 2013, Norman and Powell, 2014, 
Andress, 2007). 
Our results show that 5-weeks paricalcitol treatment in mice with established HF induced by 
TAC has a significant cardioprotective effect by halting the decline of left ventricular EF and 
the progression of pre-existing cardiac hypertrophy. Supporting our data, other authors have 
reported cardioprotective effects of paricalcitol on cardiac hypertrophy and development of 
HF in an experimental model of pressure overload in rats induced by a high-salt diet (Bae et 
al., 2011, Bodyak et al., 2007). Importantly, in the present study we comprehensively 
analysed the mechanisms involved in the beneficial effect of paricalcitol on the deleterious 
remodelling that occurs during HF development, and specifically focused on Ca2+ handling, 
myocardial fibrosis, cardiac hypertrophy and remodelling of repolarising K+ currents.  
Cardiac pump function depends on cardiomyocyte contraction, which is activated by Ca2+. 
Contraction is initiated by an action potential. The initial depolarization (mediated by Na+ 
channels) activates ICaL, which triggers Ca
2+ release from the SR, resulting in an increased 
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[Ca2+]i that activates contraction. [Ca
2+]i must be reduced for relaxation to take place, and this 
occurs mainly by pumping Ca2+ to the SR via SERCA2a and across the plasma membrane via 
the sarcolemmal Na+-Ca2+ exchanger (Bers, 2002). A decline in systolic Ca2+ release and SR-
Ca2+ load is frequently reported in HF models, which also document a reduced expression 
and/or function of SERCA2a (Bers, 2006, Gómez-Hurtado et al., 2017). In our study, ICaL 
density was not modified in any of the groups studied; however, ventricular cardiomyocytes 
isolated from failing hearts 9 weeks after TAC surgery showed diminished [Ca2+]i transients 
with a slower time decay rate (Tau) and a significant decrease in cell shortening. 
Furthermore, the caffeine-evoked [Ca2+]i transients showed a decrease in SR-Ca
2+ load. In 
this setting, paricalcitol treatment maintained the levels of [Ca2+]i transient amplitude and cell 
shortening close to that observed in the sham group. In addition, SR-Ca2+ load was preserved. 
Moreover, paricalcitol treatment suppressed the decrease in the expression of both Atp2a2 
(SERCA2a) and Pln (phospholamban) observed in TAC hearts, which likely contributed to 
maintain SR-Ca2+ content, improving [Ca2+]i transient amplitude and cell contractility. These 
data do not discard the possibility that posttranslational changes in PLN and/or SERCA2a 
might be involved in the observed effects. 
Importantly, the prevention of the impairment in both systolic Ca2+ release and SR Ca2+ load 
induced by paricalcitol administration in the TAC group can also be due to a prevention of 
the increased diastolic Ca2+ leak associated with HF development. Indeed, our results support 
this idea, since paricalcitol administration significantly prevented the increased frequency of 
Ca2+ sparks in isolated cardiomyocytes obtained from hearts of TAC-induced mice. Along 
this line, paricalcitol significantly attenuated the impairment of Ca2+ handling and cardiac 
dysfunction in mice deleted for 1α-hydroxylase (Choudhury et al., 2014), which converts the 
inactive form of vitamin D3 (25(OH)D3) to the biological active form (1,25(OH)2D3).  
Cardiac fibrosis is a distinguishing feature of pathological ventricular remodelling and can 
contribute to both systolic and diastolic cardiac dysfunction. It is characterised by 
myofibroblast differentiation and excessive synthesis and accumulation of matrix proteins, 
together with the induction of protease inhibitors, PAI-1 and tissue inhibitors of 
metalloproteinases (Kong et al., 2014, Weber et al., 1993, Takeshita et al., 2004). Indeed, it is 
well recognised that synthesis of type I and III collagens is markedly increased in the 
remodelling fibrotic heart irrespective of the aetiology of fibrosis (Weber et al., 1993, 
Mukherjee and Sen, 1993). Our histological and molecular analysis showed that paricalcitol 
treatment hindered the formation of perivascular and interstitial fibrosis 9 weeks after TAC 
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surgery. In accordance with our data, other authors have reported a role for paricalcitol in 
reducing fibrosis and remodelling in the myocardium (Meredith and McManus, 2013, Meems 
et al., 2012, Gardner et al., 2013). 
The CMRI study also showed that paricalcitol had a significant effect in preventing the 
progression of pre-existing cardiac hypertrophy, as revealed by analysis of the HW/TL ratio 
and ventricular cardiomyocyte size. Similarly, the TAC-induced increase in the expression of 
the hypertrophic gene marker Nppa (ANP) was significantly blunted by paricalcitol, further 
supporting its anti-hypertrophic activity. Indeed, anti-hypertrophic effects of paricalcitol have 
been described in other experimental models of HF (Bae et al., 2011, Kong et al., 2014, 
Bodyak et al., 2007) and in uremic rats (Freundlich et al., 2014). The mechanisms underlying 
the anti-hypertrophic effects of the VDR pathway have been investigated in cardiomyocyte-
specific VDR knockout mice, which exhibit significant cardiac hypertrophy and activation of 
the fetal gene program (Chen et al., 2011). Importantly, it has been reported that the anti-
hypertrophic activity of paricalcitol is lost in these mice after treatment with angiotensin II, 
supporting that the direct action of paricalcitol on cardiomyocytes is independent of 
hemodynamic effects (Gardner et al., 2013, Chen and Gardner, 2013). Our results clearly 
demonstrate an increase of diastolic Ca2+ leak in failing (TAC) mice. Moreover, the sustained 
elevation of the cytosolic calcium that occurs in HF has been proven to activate calcineurin-
NFAT signalling. Dephosphorylation of NFAT by calcineurin allows for NFAT to enter the 
nucleus, to promote the expression of genes involved in structural cardiac remodelling (Olson 
and Williams, 2000, Wilkins and Molkentin, 2004). Paricalcitol treatment prevented the 
impairment in diastolic Ca2+ release and SR-Ca2+ load, thus reducing the cytosolic Ca2+ 
concentration, which counteracts the activation of calcineurin/NFAT pathway. Moreover, 
results from gene expression array analysis of isolated ventricular myocytes of 
cardiomyocyte-specific VDR knockout mice showed that the expression of modulatory 
calcineurin inhibitory protein 1 (MCIP1 or Rcan1.4) was upregulated 2-fold as compared 
with control cells (Chen et al., 2011). RCANs are a family of proteins that can bind directly 
to the catalytic subunit of calcineurin and inhibit its activity. RCAN 1.4 works as an 
endogenous feedback inhibitor, protecting cells from uncontrolled calcineurin activity. The 
calcineurin/NFAT/Rcan1.4 cascade has been linked to the development of pathological 
hypertrophy in several experimental models of pressure overload (Zou et al., 2001, Wilkins et 
al., 2004, Diedrichs et al., 2004) and also in human HF (Lim and Molkentin, 1999, Diedrichs 
et al., 2004). In the present study, we found that the increase in Rcan1.4 mRNA expression in 
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hypertrophied hearts from TAC mice was blunted by paricalcitol treatment, suggesting that 
the VDR-dependent antihypertrophic activity of paricalcitol is linked to the negative 
modulation of the calcineurin/NFAT/Rcan1.4 pathway. A similar inhibition of the NFAT 
target gene Rcan1.4 associated with reduced cardiac hypertrophy was recently reported in 
paricalcitol-treated uremic rats (Czaya et al., 2019). 
LVH and HF are associated with QT prolongation and increased susceptibility for ventricular 
arrhythmias (Nass et al., 2008, Tomaselli and Marbán, 1999). Indeed, about 50% of the 
mortality in patients with HF is reported to be associated with sudden cardiac death, which is 
often related to malignant ventricular arrhythmias (Nass et al., 2008, Tomaselli et al., 1994). 
In addition, prolonged TpTe interval has been associated with increased risk of sudden 
cardiac death in patients (Panikkath et al., 2011). Therefore, in addition to the QT interval, we 
examined other electrocardiographic parameters associated with ventricular repolarization, 
finding that the QT, JT and TpTe intervals were significantly prolonged in TAC-operated 
mice, whereas TAC-induced mice receiving paricalcitol showed a significant decrease in the 
duration of the three intervals. The mechanism for prolongation of ventricular repolarization 
in HF involves the development of adverse electrophysiological remodelling including 
downregulation of K+ currents responsible for repolarization of the action potential (Nattel et 
al., 2007). Using patch-clamp experiments we found that the density of IK
+, Itof, Ikur and Iss 
were significantly lower in myocytes isolated from TAC mice than in sham or sham 
paricalcitol groups. Treatment of TAC mice with paricalcitol prevented this decrease mainly 
for IK+ and Itof. A reduction in Itof density has been reported in animal models of HF (Gómez-
Hurtado et al., 2017, Wang et al., 2007) and in humans (Beuckelmann et al., 1993, Näbauer et 
al., 1993). Our results thus establish that paricalcitol reduces QT, JT and Tp Te interval 
prolongation associated with LVH and HF by preventing deleterious electrophysiological 
remodelling. Therefore, through this mechanism, paricalcitol might attenuate the 
vulnerability to LVH/HF-associated ventricular arrhythmias. 
In conclusion, we provide the first demonstration that paricalcitol, a drug used for the 
treatment of secondary hyperparathyroidism, prevents the progression of established HF by 
alleviating LVH, cardiac fibrosis and adverse electrophysiological and Ca2+ handling 
remodelling. Our results suggest that paricalcitol might emerge as a potential therapeutic 
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Table 1: Macroscopic parameters, cell capacitance, and serum analysis from each 
experimental group 9 weeks after surgery. Values are expressed as Mean ± SEM. #p<0.05 vs 
Sham-vehicle. & p<0.05 vs TAC-vehicle.  PTH = parathyroid hormone. HW = heart weight. 










] 12.5 ± 0.6  (N= 16) 11.4 ± 0.6 (N= 8) 11.0 ± 0.6  (N= 15) 12.4 ± 0.5 (N= 14) 
PTH [pg mL
-1
] 145.2 ± 17.4 





123.0 ± 12.4  
(N= 14) 
52.8 ± 3.4 
&
  





] 8.6 ± 0.5 (N= 15) 6.8 ± 0.7 (N= 9) 7.1 ± 0.7  
(N= 15) 8.0 ± 0.5 (N= 15) 
Ratio (HW TL
-1




12.1 ± 0.6 
&
  
(N= 14)  
HW (mg) 174.6 ± 5.9  
(N= 13) 
180.3 ± 7.1  
(N= 12) 








TL (mm) 17.6 ± 0.2 (N= 13) 18.2 ± 0.2 (N= 12) 17.9 ± 0.2 
# 
 (N= 15)  
17.7 ± 0.2 
&
  
(N= 14)  
Cell area (μm
2
) 3251 ± 121.0  
(N=6; n=72) 
3422 ± 159.1 
(N=5; n=45) 
4555 ± 167.4 
# 
(N=6; n=78) 
3941 ± 177.1 
& 
(N=6; n=56) 
Capacitance (pF) 186.3 ± 16.8 
(N=5; n=13) 
189.7 ± 15.8 
(N=5; n=10) 
375.9 ± 39.6 
# 
(N=5; n=12) 
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Figure 2. Stage of the disease before paricalcitol treatment analysed by cardiac magnetic 
resonance imaging (CMRI). (A) Left ventricular mass (LVM), (B) left ventricular end 
diastolic volume (LVEDV), (C) Left ventricular end systolic volume (LVESV), (D) Ejection 
fraction (EF). There were no differences between the TAC and TAC PC groups in any 
parameter before the treatment was initiated. Sham (N=16), sham PC (N=15), TAC (N=14) 
and TAC PC (N=16). Data expressed as mean±SD. +p<0.05 both groups Sham vs. both 
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Figure 3. Paricalcitol blocks pathological progression of heart failure. (A) Representative 
cardiac magnetic resonance (CMR) images of mouse hearts at the end of diastole. Top, 4-
chamber long-axis views; bottom, 2-chamber short-axis views. (B) CMR analysis of left 
ventricular mass (LVM), (C) left ventricular end diastolic volume (LVEDV), (D) left 
ventricular end systolic volume (LVESV) and (E) ejection fraction (EF). Groups are sham 
(N=16), sham PC (N=15), TAC (N=14) and TAC PC (N=16). Data expressed as mean±SEM. 
*p<0.05 vs TAC 4w. &p<0.05 TAC 9w vs. TAC PC 9w. Each TAC group was statistically 
different from each sham group p<0.05. N = number of mice. PC = paricalcitol. Scale bar 
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Figure 4. Paricalcitol treatment attenuates [Ca2+]i mishandling in isolated myocytes from 
hearts after 9 weeks of TAC. (A) Current-voltage curves for ICaL density obtained in 
myocytes isolated from sham (n=13, N=4), sham PC (n=10, N=4), TAC (n=12, N=4) and 
TAC PC (n=15, N=4) groups. The upper panel shows the protocol used to elicit ICaL. (B) 
Representative line-scan confocal images of transients stimulated to 2 Hz in cells from sham, 
sham PC, TAC and TAC PC groups. (C) Mean values of peak of fluorescence [Ca2+]i 
transients (Peak F/F0), (D) decay time constant (tau) and (E) cell shortening in sham (n=42, 
N=6), sham PC (n=42, N=5), TAC (n=62, N=6) and TAC PC (n=58, N=6) groups. (F) Mean 
values of amplitude SR-Ca2+ load (Peak F/F0) are shown in sham (n=24, N=6) sham PC 
(n=26, N=5), TAC (n=34, N=6) and TAC PC (n=29, N=6) groups. (G) Paricalcitol treatment 
increases mRNA expression of Atp2a2 (SERCA2a) and (H) Pln (Phospholamban) 9 weeks 
after TAC surgery. Sham (N=7), Sham PC (N=5), TAC (N=7) and TAC PC (N=6). Data 
expressed as mean ±SEM in panel A and mean±SD in panels C-H. #p<0.05 Sham vs. TAC 
&p<0.05 TAC vs TAC PC. Sham vs. Sham PC groups were not significantly different. N = 
number of mice; n = number of independent cardiomyocytes. PC = paricalcitol. 
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Figure 5. Paricalcitol treatment inhibits the progression of both perivascular and interstitial 
cardiac fibrosis by preventing the increased expression of serpine1, Col1a1 and Col3a1. (A, 
B) Representative images of sirius red staining showing perivascular (A) and interstitial (B) 
fibrosis from each experimental group 9 weeks after the surgery. (C) Paricalcitol treatment 
attenuates the increase of perivascular fibrosis (normalised by luminal area). Groups are sham 
(n=49, N=9), sham PC (n=57, N=9), TAC (n=43, N=9) and TAC PC (n=60, N=10). (D) 
Interstitial fibrosis is also diminished by paricalcitol treatment. Groups are sham (N=9), sham 
PC (N=9), TAC (N=9) and TAC PC (N=10). (E,F,G) Real-time PCR analysis of mRNA 
expression of serpine1, col1a1 and col3a1. Groups are sham (N=7), sham PC (N=5), TAC 
(N=7) and TAC PC (N=6). Data expressed as mean±SD. #p<0.05 sham vs TAC; &p<0.05 
TAC vs TAC PC. $p<0.05 sham PC vs. TAC PC. Sham vs. Sham PC groups were not 
significantly different PVCA = Perivascular collagen area. LA = luminal area. N = number of 
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Figure 6. Paricalcitol treatment blunts hypertrophic development by attenuating the 
calcineurin/Rcan1.4 pathway (A) Representative examples of histological images of whole-
hearts in axial views from sham, sham PC, TAC and TAC PC mice (B) Representative 
confocal microscopy images of adult cardiomyocytes. (C) TAC PC treated group has a ratio 
of HW (mg) to TL (mm) lower than that of the TAC group. Groups are sham (N=13), sham 
PC (N=12), TAC (N=15) and TAC PC (N=15). (D) Paricalcitol prevents cardiomyocyte 
hypertrophy. Groups are sham (n=72, N=6), sham PC (n=45, N=5), TAC (n=78, N=6) and 
TAC PC (n=56, N=6). (E, F) Real-time PCR analysis of mRNA expression of Nppa and 
Rcan1.4. Groups are sham (N=7), sham PC (N=5), TAC (N=7) and TAC PC (N=6). Data 
expressed as mean±SD. #p<0.05 sham vs. TAC. &p<0.05 TAC vs TAC PC. HW = heart 
weight. TL = tibia length. N = number of mice. n = number of independent cardiomyocytes. 
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Figure 7. Long QT, JT and TpTe intervals associated with TAC 9 weeks after the surgery are 
prevented by paricalcitol treatment. (A) Representative examples of baseline ECG and QT 
interval measurement, (B) QT intervals,(C) HR, (D) JT interval and (E) TpTe interval values 
obtained in sham, sham PC, TAC and TAC PC groups 9 weeks after the surgery. Sham 
(N=6), sham PC (N=5), TAC (N=7) and TAC PC (N=8). Data expressed as mean± SD. 
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Figure 8. Paricalcitol treatment blocks the reduction of IK+ density and Itof in myocytes 
isolated from mice 9 weeks after TAC surgery. (A). Representatives records of IK+ density 
obtained in 4 different myocytes isolated from sham, sham PC, TAC and TAC PC mice. The 
upper panel shows the protocol used to elicit IK+. (B-E). Current density-voltage curves for 
IK+ (B) Itof, (C) Ikur (D) and Iss (E), obtained on myocytes isolated from sham, sham PC, TAC 
and TAC PC. Panel (F-G) shows individual values of Itof, Ikur and Iss densities recorded at +50 
mV. Data expressed as mean±SEM for I/V curves and mean ±SD for data at +50 mV. Sham 
(n= 13 for IK+, n=13 for Itof, n=10 for Ikur and n=14 for Iss), sham PC (n= 10 for IK+, n=9 for 
Itof, n=10 for Ikur and n=11 for Iss), TAC (n= 12 for IK+, n=19 for Itof, n=15 for Ikur and n=15 
for Iss) and TAC PC (n= 15 for IK+, n=16 for Itof, n=11 for Ikur and n=13 for Iss) #p<0.05 sham 
vs TAC. &p<0.05 TAC vs TAC PC. n.s. = non-significant. n = number of independent 
cardiomyocytes. PC = paricalcitol 
 
